Hello – Nuclear power is shifting from a distant promise to an immediate growth story. U.S. energy plans call for tripling reactor capacity over the next 25 years, and major data-center operators are already reserving small modular reactors (SMRs)to secure reliable, low-cost, carbon-free power. To help investors get ahead of this accelerating trend, we’ve released an updated report: 7 Top Nuclear Stocks to Buy Now. Inside, you’ll learn about:
The only U.S. company licensed to produce next-gen HALEU fuel—a critical component for SMRs and advanced reactors The SMR developer already contracted for two gigawatt-scale data-center projects in Ohio and Pennsylvania An all-in-one ETF that bundles utilities, uranium miners, fuel suppliers, and breakthrough innovators into a single trade These seven names give you exposure to uranium mining, fuel enrichment, reactor construction and the steady cash flow of government contracts—all in one concise, easy-to-read guide. 👉 Download your complimentary PDF now. No cost, no strings—just timely research before the mainstream spots the opportunity. Let’s get you ahead of the trend, Matthew Paulson
Founder & CEO, MarketBeat P.S. Regulations can slow nuclear projects, but early investors could ride this multi-decade tailwind for years. Grab the list now and decide which of these seven leaders earns a place in your portfolio.
Additional Reading from MarketBeat.com
Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?By Jessica Mitacek. Published: 5/12/2026. 
Key Points
- Hims & Hers shares plunged over 12% in after-hours trading after reporting a Q1 double-miss, with an EPS loss of negative 40 cents versus four cents expected and year-over-year revenue growth of just 3.8%.
- The company is seeing success with its Novo Nordisk partnership, fulfilling over 125,000 Wegovy shipments in Q1, and planning to bolster its global footprint through the acquisition of Eucalyptus.
- Management raised full-year guidance and reiterated ambitious 2030 revenue targets, supported by operating in high-growth telehealth and weight-loss markets that are projected to expand significantly through the end of the decade.
- Special Report: Elon Musk already made me a “wealthy man”
Shares of telehealth provider Hims & Hers Health (NYSE: HIMS) sold off sharply after the company reported disappointing Q1 FY2026 financial results. Shares fell more than 12% in after-hours trading following the May 11 release. Expectations for the quarter were high, particularly after the company partnered with Danish pharmaceutical giant Novo Nordisk (NYSE: NVO).
Your Download Link (Expiring)
If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires.
That way, no matter what it costs in the future, you'll have a free copy on your computer. Simple Options Trading For Beginners (Download Link Expires)...
In March, Novo Nordisk dismissed its patent infringement lawsuit against Hims & Hers Health and entered into a partnership with the company to sell its GLP-1 weight loss drugs Wegovy and Ozempic on the telehealth platform. But that wasn’t enough to prevent the company from posting a double miss in its Q1 report. The results marked the company’s fourth miss on both earnings and revenue in the past five quarters. Shares of HIMS are now down more than 50% over the past year, including a loss of nearly 20% year-to-date. The Losing Streak Continues for Hims & Hers HealthOn Monday, the company reported a Q1 earnings per share (EPS) loss of 40 cents, missing analyst expectations by a wide margin. Quarterly revenue came in at $608.10 million, also below the consensus estimate of $616.84 million. Concerningly, the figure represents just 3.8% year-over-year revenue growth. The company attributed the slow revenue growth and earnings loss to approximately $33 million in restructuring charges, including a roughly $28 million write-down tied to the GLP-1 compounding pivot. The earnings report wasn’t all bad news, though. Hims & Hers Health highlighted how its GLP-1 strategy pivot with Novo Nordisk is already bearing fruit. The company fulfilled more than 125,000 Wegovy shipments in Q1 and is on track to add more than 100,000 new weight-loss subscribers per month. Hims & Hers also noted that international expansion is becoming an increasingly important strategic focus. The acquisition of Eucalyptus is expected to be completed in the second half of the year, broadening the company’s global footprint and supporting its 2030 targets of at least $6.5 billion in annual revenue and $1.3 billion in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA). In his earnings call comments, CEO Andrew Dudum said the company’s growing international reach is becoming a competitive advantage because it expands its total addressable market, increases its value to industry partners, and strengthens platform network effects. Perhaps most importantly for buy-and-hold investors, management raised full-year revenue guidance to a range of $2.8 billion to $3 billion and adjusted EBITDA guidance to $275 million to $350 million. Dudum added that “2026 is proving to be a year of accelerating growth, which reinforces our confidence in our ambitious 2030 targets.” Hims & Hers Remains a Growth StoryThe company sits at the intersection of multiple high-growth markets. According to industry consultancy Grand View Research, the global weight loss supplement market, valued at $33.14 billion in 2024, is expected to grow at a compound annual growth rate (CAGR) of 14.17% from 2025 to 2030, reaching nearly $72 billion. Grand View Research forecasts that the global telehealth market will grow even faster, with a CAGR of 24.68% from 2025 to 2030. That would increase its value from just over $123 billion in 2024 to more than $455 billion by the end of the forecast period. And while growth in the global hair thinning market is not expected to be as pronounced as in the telehealth and weight loss markets, Grand View Research still projects a CAGR of 10.85% from 2025 to 2030. Those projected growth rates bode well for Hims & Hers Health, which is transitioning from a niche wellness brand into a comprehensive, technology-driven healthcare platform. The company is also expanding into cardiovascular screenings, preventative care, dermatology, and diagnostic partnerships. The Long-Term Prospects Remain PositiveDespite the recent selloff, analyst sentiment remains mostly positive. While the stock carries a consensus Hold rating, its average 12-month price target suggests more than 15% potential upside. The high-end price target of $60 implies as much as 100% potential upside, while the low-end price target of $18 suggests HIMS could see additional losses of around 38%. In the short term, traders should expect more volatility ahead. Current short interest is concerningly high at more than 31%. And while institutional activity slowed dramatically in Q1, sellers outnumbered buyers in Q4 FY2025, with outflows of $861 million easily surpassing inflows of $318 million. At the same time, the stock has seen insider buying disappear, while insider selling has totaled nearly $125 million over the past year. That has pushed down insider ownership to less than 13%. With a trailing 12-month EPS of 51 cents and a forward price-to-earnings ratio of around 48, Hims & Hers Health’s earnings are expected to grow more than 26% over the next year, from 53 cents per share to 67 cents per share. |
Post a Comment
Post a Comment